Frontlight ResearchEarly access
Multiple myeloma trials in United States
246 of 297 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleA Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
- Where
- Houston
- Age
- 18 years and over
- People
- 30
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT05055063 - Phase 3Taking peopleA Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- Where
- Bethesda, Bullhead City, Canton, Greenville, Huntington Park, Morrisville, Rockville, St. Petersburg, Wilson
- Age
- 18 years and over
- People
- 386 worldwide
- Run by
- Grifols Therapeutics LLC
See details and how to joinNCT05645107 · EU 2022-502193-16-00 - Phase 2Taking people18F-Fluciclovine PET/CT in Multiple Myeloma
- Where
- Bethesda
- Age
- 18 years to 120 years
- People
- 60
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT06103838 - Phase 3Taking peopleMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Where
- Belton, Beverly Hills, Boston, Chicago, Cincinnati, Cleveland, Clovis, Coral Gables, Dallas, Deerfield Beach, Doral, Encino, Evanston, Fargo, Fort Collins, Fresno, Glenview, Greeley, Greenville, Hawthorne, Highland Park, Hollywood, Houston, Independence, Indianapolis, Irvine, Kansas City, Lake Success, Leawood, Lincoln, Longmont, Los Angeles, Loveland, Lubbock, Madison, Manhasset, Merriam, Miami, Mobile, Morgantown, Nashville, New Hyde Park, Newport Beach, Panorama City, Pittsburgh, Plantation, Providence, Sacramento, Springfield, Sugar Land, Tamarac, Temple, The Woodlands, Valhalla, Zion
- Age
- 18 years and over
- People
- 492 worldwide
- Run by
- Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00 - Phase 3Taking peopleBelantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
- Where
- Brewer, Des Moines, La Crosse
- Age
- 18 years to 79 years
- People
- 500
- Run by
- PrECOG, LLC.
See details and how to joinNCT07285239 - No phaseNot yet taking people in United StatesPre-Transplant Nutrition Counseling in Patients With Multiple Myeloma
- Where
- Salt Lake City
- Age
- 18 years and over
- People
- 20
- Run by
- University of Utah
See details and how to joinNCT07932301 - Phase 1Taking peopleA Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Aurora, Austin, Chapel Hill, Cincinnati, Dallas, Eugene, Fairfax, Fort Wayne, Hinsdale, Houston, Indianapolis, Lincoln, Metairie, Nashville, Newark, New York, Omaha, Phoenix, Rochester, Seattle, Springdale, Tacoma, Tyler, Winston-Salem
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- AbbVie
See details and how to joinNCT05650632 · EU 2023-504674-38-00 - Phase 3Taking peopleCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Where
- Atlanta, Charlotte, Chicago, Cincinnati, Duarte, Houston, Irvine, Milwaukee, Morgantown, New Haven, Philadelphia, Washington D.C., Winston-Salem
- Age
- 18 years and over
- People
- 380 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00 - No phaseTaking peopleNon-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
- Where
- Buffalo
- Age
- 18 years and over
- People
- 265
- Run by
- Roswell Park Cancer Institute
See details and how to joinNCT05312255 - Phase 3Active, not recruitingA Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Charlotte, Durham, Gainesville, Houston, Lexington, Los Angeles, Louisville, Portland, Seattle, Stony Brook
- Age
- 18 years and over
- People
- 410 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00 - Phase 2Taking peopleAt-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
- Where
- Grand Forks, Jacksonville
- Age
- 18 years and over
- People
- 220
- Run by
- Mayo Clinic
See details and how to joinNCT05969860 - Phase 2Taking peopleEngaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
- Where
- New Haven, Omaha, Rochester
- Age
- 18 years and over
- People
- 50
- Run by
- Noffar Bar
See details and how to joinNCT06993675 - Phase 1Taking peopleA Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Where
- Atlanta, Boston, Chapel Hill, Columbus, Dallas, Detroit, Indianapolis, La Jolla, New York, Rochester, Seattle, Winston-Salem
- Age
- 18 years and over
- People
- 317 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05137054 · EU 2023-506247-42-00 - No phaseNot yet taking people in United StatesWearable Core Body Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Outpatients Receiving CAR T-Cell Therapy
- Where
- Charlotte, Winston-Salem
- Age
- 18 years and over
- People
- 105
- Run by
- Wake Forest University Health Sciences
See details and how to joinNCT07911540 - Phase 2Taking peopleTesting the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
- Where
- Anaconda, Baton Rouge, Billings, Bloomington, Canton, Carthage, Cedar Rapids, Coeur d'Alene, Decatur, Eureka, Galesburg, Great Falls, Kalispell, Kewanee, Macomb, Missoula, O'Fallon, Ottawa, Pekin, Peoria, Peru, Post Falls, Princeton, Sandpoint, Springfield, Washington
- Age
- 18 years and over
- People
- 80
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT06948084 - Phase 2Taking peopleBCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
- Where
- Milwaukee
- Age
- 18 years and over
- People
- 34
- Run by
- Medical College of Wisconsin
See details and how to joinNCT07009899 - Phase 1Taking peopleFT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
- Where
- Milwaukee
- Age
- 18 years to 80 years
- People
- 12
- Run by
- Medical College of Wisconsin
See details and how to joinNCT07221032 - Phase 3Taking peopleA Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Where
- Atlanta, Columbus, Dallas, Houston, New York, Stony Brook
- Age
- 18 years and over
- People
- 915 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00 - Phase 3Taking peopleA Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Where
- Atlanta, Boston, Columbus, Detroit, New York, Phoenix, Rochester, St Louis
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07393282 · EU 2025-523252-31-00 - Phase 2Taking peopleA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Ann Arbor, Atlanta, Birmingham, Chicago, Duarte, Hollywood, Little Rock, Louisville, Nashville, New York, Portland, Rochester, St Louis
- Age
- 18 years and over
- People
- 510 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00 - Phase 4Taking peopleA Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Where
- Atlanta, Boston, Buffalo, Charlotte, Chicago, Detroit, Duarte, Hackensack, Houston, Indianapolis, Milwaukee, Nashville, New Brunswick, New York, Philadelphia, Phoenix, Pittsburgh, Rochester, San Francisco, Stanford, St Louis, Tampa, The Bronx, Westwood
- Age
- 18 years and over
- People
- 295 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00 - Phase 3Taking peopleA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Ann Arbor, Baltimore, Bethesda, Charleston, Charlotte, Charlottesville, Chicago, Cincinnati, Cleveland, Clovis, Columbus, Dallas, Detroit, Duarte, Durham, East Brunswick, East Syracuse, Farmington, Fort Belvoir, Gilbert, Grand Rapids, Hershey, Hollywood, Houston, Irvine, Kansas City, Lake Success, Lebanon, Los Alamitos, Los Angeles, Louisville, Lubbock, Maywood, Mineola, Nashville, Newark, New Haven, Newnan, New York, Norfolk, Novi, Omaha, Orlando, Pittsburgh, Providence, Richmond, Salt Lake City, Santa Fe, Shreveport, Southfield, Tacoma, Tucson, Waukee, Weston, Wilmington, Winston-Salem
- Age
- 18 years and over
- People
- 1,590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00 - Phase 1Taking peopleA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Where
- Charlotte, Denver, Duarte, Houston, Irvine, New York, Philadelphia, San Francisco
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00 - Phase 2Taking peopleA Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
- Where
- Charlotte, Cleveland, Iowa City, New York, San Francisco, Tampa, Winston-Salem
- Age
- 18 years to 80 years
- People
- 60 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07149857 · EU 2025-521975-30-00 - Phase 3Taking peopleA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Ann Arbor, Atlanta, Austin, Baltimore, Boston, Brooklyn, Chapel Hill, Cleveland, Dallas, Denver, Duarte, Durham, Farmington, Fort Myers, Houston, Iowa City, Irvine, Jacksonville, Kansas City, Little Rock, Los Angeles, Louisville, Miami, Milwaukee, Mineola, Nashville, New Haven, New York, Philadelphia, Phoenix, Portland, Rochester, Salt Lake City, San Antonio, San Francisco, Tampa, Waukee, Zion
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00